Delving into the Latest Updates on Shanghai Institute of Biological Products Co., Ltd. with Synapse

Overview

Tags

Infectious Diseases

Neoplasms

Respiratory Diseases

Prophylactic vaccine

Live attenuated vaccine

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	12
Neoplasms	8
Immune System Diseases	4
Hemic and Lymphatic Diseases	3
Endocrinology and Metabolic Disease	2

Top 5 Drug Type	Count

Prophylactic vaccine	11
Live attenuated vaccine	7
Monoclonal antibody	5
Inactivated vaccine	3
Biosimilar	3

Top 5 Target	Count

HER3(Receptor tyrosine-protein kinase erbB-3)	2
CD20(B-lymphocyte antigen CD20)	1
VEGF-A(Vascular endothelial growth factor A)	1
Uric acid	1
CD20 x CD3	1

The increasing incidence of diseases caused by Coxsackievirus A6 (CV-A6) and the presence of various mutants in the population present significant public health challenges. Given the concurrent development of multiple vaccines in China, it is challenging to objectively and accurately evaluate the level of neutralizing antibody response to different vaccines. The choice of the detection strain is a crucial factor that influences the detection of neutralizing antibodies. In this study, the National Institutes for Food and Drug Control collected a prototype strain (Gdula), one subgenotype D1, as well as 13 CV-A6 candidate vaccine strains and candidate detection strains (subgenotype D3) from various institutions and manufacturers involved in research and development. We evaluated cross-neutralization activity using plasma from naturally infected adults (n = 30) and serum from rats immunized with the aforementioned CV-A6 strains. Although there were differences between the geometric mean titer (GMT) ranges of human plasma and murine sera, the overall trends were similar. A significant effect of each strain on the neutralizing antibody test (MAX/MIN 48.0 ∼16410.3) was observed. Among all strains, neutralization of the S112 strain by 15 different sera resulted in higher neutralizing antibody titers (GMT_S112= 132.0) and more consistent responses across different genotypic immune sera (MAX/MIN = 48.0). Therefore, S112 may serve as a detection strain for NtAb testing in various vaccines, minimizing bias and making it suitable for evaluating the immunogenicity of the CV-A6 vaccine.

01 Aug 2024·Archives of Virology

A synthetic TLR4 agonist significantly increases humoral immune responses and the protective ability of an MDCK-cell-derived inactivated H7N9 vaccine in mice

Article

Author: Zhang, Min ; Zhao, Liang ; Wang, Qi ; Gao, Feixia ; Li, Beibei ; Ye, Qian ; Luo, Jian ; Tan, Wen-Song ; Xu, Wenting

Antigenically divergent H7N9 viruses pose a potential threat to public health, with the poor immunogenicity of candidate H7N9 vaccines demonstrated in clinical trials underscoring the urgent need for more-effective H7N9 vaccines. In the present study, mice were immunized with various doses of a suspended-MDCK-cell-derived inactivated H7N9 vaccine, which was based on a low-pathogenic H7N9 virus, to assess cross-reactive immunity and cross-protection against antigenically divergent H7N9 viruses. We found that the CRX-527 adjuvant, a synthetic TLR4 agonist, significantly enhanced the humoral immune responses of the suspended-MDCK-cell-derived H7N9 vaccine, with significant antigen-sparing and immune-enhancing effects, including robust virus-specific IgG, hemagglutination-inhibiting (HI), neuraminidase-inhibiting (NI), and virus-neutralizing (VN) antibody responses, which are crucial for protection against influenza virus infection. Moreover, the CRX-527-adjuvanted H7N9 vaccine also elicited cross-protective immunity and cross-protection against a highly pathogenic H7N9 virus with a single vaccination. Notably, NI and VN antibodies might play an important role in cross-protection against lethal influenza virus infections. This study showed that a synthetic TLR4 agonist adjuvant has a potent immunopotentiating effect, which might be considered worth further development as a means of increasing vaccine effectiveness.

01 Apr 2024·Biochemical and Biophysical Research Communications

Is myeloid-derived growth factor a ligand of the sphingosine-1-phosphate receptor 2?

Article

Author: He, Cheng ; Guo, Zhan-Yun ; Xu, Zeng-Guang ; Zheng, Yong-Shan ; Liu, Ya-Li

Secretory myeloid-derived growth factor (MYDGF) exerts beneficial effects on organ repair, probably via a plasma membrane receptor; however, the identity of the expected receptor has remained elusive. In a recent study, MYDGF was reported as an agonist of the sphingosine-1-phosphate receptor 2 (S1PR2), an A-class G protein-coupled receptor that mediates the functions of the signaling lipid, sphingosine-1-phosphate (S1P). In the present study, we conducted living cell-based functional assays to test whether S1PR2 is a receptor for MYDGF. In the NanoLuc Binary Technology (NanoBiT)-based β-arrestin recruitment assay and the cAMP-response element (CRE)-controlled NanoLuc reporter assay, S1P could efficiently activate human S1PR2 overexpressed in human embryonic kidney (HEK) 293T cells; however, recombinant human MYDGF, overexpressed either from Escherichia coli or HEK293 cells, had no detectable effect. Thus, the results demonstrated that human MYDGF is not a ligand of human S1PR2. Considering the high conservation of MYDGF and S1PR2 in evolution, MYDGF is also probably not a ligand of S1PR2 in other vertebrates.

100 Deals associated with Shanghai Institute of Biological Products Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Institute of Biological Products Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

IND Approval

Phase 1 Clinical

5

2

Phase 2 Clinical

Phase 3 Clinical

1

NDA/BLA

Approved

12

5

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Rubella vaccine, live-attenuated(Shanghai Institute of Biological Products)	Rubella More	Approved
Measles Vaccine,Live(Shanghai Institute of Biological Products Co., Ltd.)	Measles More	Approved
Tetravalent influenza vaccine (Shanghai Institute of Biological Products)	Influenza, Human More	Approved
Influenza vaccine (split virion, inactivated), Shanghai Institute of Biological Products(Shanghai Institute of Biological Products Co., Ltd.)	Influenza, Human More	Approved
Recombinant human interferon alpha-1b(Shanghai Institute of Biological Products) ( IFNAR-1 )	Hairy Cell Leukemia More	Approved